



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 231/14, C07D 305/12, C07C 55/32, 309/63, 259/06		A1	(11) International Publication Number: WO 98/43946
			(43) International Publication Date: 8 October 1998 (08.10.98)
(21) International Application Number: PCT/GB98/00913		(74) Agent: DENERLEY, Paul, Millington; Zeneca Pharmaceuticals, Intellectual Property Dept., Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).	
(22) International Filing Date: 25 March 1998 (25.03.98)			
(30) Priority Data: 97400724.7 28 March 1997 (28.03.97) EP		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(34) Countries for which the regional or international application was filed: AT et al.			
(71) Applicants (for all designated States except US): ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB). ZENECA PHARMA S.A. [FR/FR]; "Le Galien", 1, rue des Chauffours, Boîte postale 127, F-95022 Cergy Cedex (FR).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): BIRD, Thomas, Geoffrey, Colerick [GB/FR]; Centre de Recherches, Zone industrielle la Pompelle, Chemin de Vrilly, Boîte postale 1050, F-51689 Reims Cedex 2 (FR). PASQUET, Marie-Jeanne [FR/FR]; Centre de Recherches, Zone industrielle la Pompelle, Chemin de Vrilly, Boîte postale 1050, F-51689 Reims Cedex 2 (FR). PELLETER, Jacques [FR/FR]; Centre de Recherches, Zone industrielle la Pompelle, Chemin de Vrilly, Boîte postale 1050, F-51689 Reims Cedex 2 (FR).		Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	
(54) Title: PROCESS FOR THE PREPARATION OF N-(3-HYDROXY-SUCCINYL)-AMINO ACID DERIVATIVES			
(57) Abstract			
Processes for preparing compounds of the formula (I) are described: $P^1OOC-CH(OH)-CHR^1-CONH-Z$ wherein P^1 is hydrogen or a protecting group, Z is a group $-CHR^2COOP^2$ or $-CHR^2CONR^3R^4$ wherein P^2 is hydrogen or a protecting group and R^1-R^4 are values known in the TNF-inhibitor art. The compounds of the formula (I) are useful in inhibiting TNF and one or more matrix metalloproteinase enzymes. One intermediate in a process of the invention is formula (II).			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

PROCESS FOR THE PREPARATION OF N-(3-HYDROXY-SUCCINYL)-AMINO ACID DERIVATIVES

This invention relates to a chemical process and to chemical intermediates useful in such a process.

5 The chemical process of this invention is useful for preparing compounds which are inhibitors of the production of TNF (Tumour Necrosis Factor) which is believed to be formed by the cleavage of a pro-form, or larger precursor, by the enzyme pro-TNF Convertase. The chemical process of this invention is also useful for preparing compounds which are intermediates in the production of compounds which are inhibitors of the production of TNF.


10 Compounds which are inhibitors of the production of TNF will be useful in the treatment of disease or medical conditions in which excessive TNF production is known to give rise via a cascade of processes to a variety of physiological sequelae including the production of physiologically-active eicosanoids such as the prostaglandins and leukotrienes, the stimulation of the release of proteolytic enzymes such as collagenase, the activation of
15 osteoclast activity leading to the resorption of calcium, the stimulation of the release of proteoglycans from, for example, cartilage, the stimulation of cell proliferations and to angiogenesis. It is also known that, in certain cellular systems, TNF production precedes and mediates the production of other cytokines such as interleukin-1 (IL-1) and interleukin-2 (IL-2) which are also believed to contribute to the pathology of disease states such as
20 inflammatory and allergic diseases and cytokine-induced toxicity. Excessive TNF production has also been implicated in mediating or exacerbating the development of various inflammatory and allergic diseases such as inflammation of the joints (especially rheumatoid arthritis, osteoarthritis and gout), inflammation of the gastrointestinal tract (especially inflammatory bowel disease, ulcerative colitis and gastritis), skin disease (especially psoriasis,
25 eczema and dermatitis) and respiratory disease (especially asthma, bronchitis and allergic rhinitis), and in the production and development of various cardiovascular disorders such as myocardial infarction, angina and peripheral vascular disease. Excessive TNF production has also been implicated in mediating complications of bacterial, fungal and/or viral infections such as endotoxic shock, septic shock and toxic shock syndrome. Excessive TNF production
30 has also been implicated in mediating or exacerbating the development of adult respiratory distress syndrome, diseases involving cartilage or muscle resorption, Paget's disease and

- 2 -

osteoporosis, pulmonary fibrosis, cirrhosis, renal fibrosis, the cachexia found in certain chronic diseases such as malignant disease and acquired immune deficiency syndrome (AIDS), tumour invasiveness and tumour metastasis and multiple sclerosis.

The compounds able to be prepared by the process of this invention may also be
5 inhibitors of one or more matrix metalloproteinases such as collagenases, stromelysins and gelatinases. Thus they may also be of use in the therapeutic treatment of disease conditions mediated by such enzymes for example arthritis (rheumatoid and osteoarthritis), osteoporosis and tumour metastasis.

The present invention relates, more specifically, to a process for preparing compounds
10 of the formula (I):



wherein P^1 is hydrogen, a salt forming cation or a protecting group, Z is a group
15 $\text{-CHR}^2\text{COOP}^2$ or $\text{-CHR}^2\text{CONR}^3\text{R}^4$ wherein P^2 is hydrogen or a protecting group and $\text{R}^1\text{-R}^4$ are values known in this structural type of TNF inhibitor.

The compounds of the formula (I), when Z is $\text{-CHR}^2\text{CONR}^3\text{R}^4$ and P^1 is hydrogen or a salt-forming cation are active TNF inhibitors.

The compounds of the formula (I) wherein P^1 is hydrogen or a salt-forming cation
20 may also be converted to the corresponding hydroxamic acid of the formula (II):



wherein R^1 and Z are as hereinbefore defined.

25 Compounds of the formulae (II) wherein Z is $\text{-CHR}^2\text{CONR}^3\text{R}^4$ are known TNF inhibitors. Compounds of the formula (II) wherein Z is $\text{-CHR}^2\text{COOP}^2$ may be converted to compounds of the formula (II) wherein Z is $\text{-CHR}^2\text{CONR}^3\text{R}^4$ by standard methods.

Compounds of the formulae (I) and/or (II), wherein Z is $\text{-CHR}^2\text{CONR}^3\text{R}^4$ are disclosed as TNF inhibitors for example in: WO 9633165, WO 9616931, WO 9606074,
30 WO 9532944, WO 9519961, WO 9519957, WO 9519956, WO 9424140, WO 9402447, WO 9402446, WO 9533709, EPA 497192, EPA 236872, WO 9633176, WO 9633968,

WO 9506031 and WO 9522966.


Accordingly the present invention provides a process for preparing a compound of the formula (I) or a salt thereof:

5



wherein P^1 is hydrogen or a protecting group;

Z is a group $-\text{CHR}^2\text{COOP}^2$ or $-\text{CHR}^2\text{CONR}^3\text{R}^4$ wherein P^2 is hydrogen or a protecting group
10 and R^1-R^4 are values known in the afore-mentioned disclosures, which process comprises reacting a compound of the formula (III):



15 wherein L is a leaving group, with a compound of the formula (IV):



and thereafter if necessary:

- 20 i) removing any protecting groups,
ii) forming a salt.


L is a leaving group. Suitably L is a leaving group such as halo, for example chloro, bromo or iodo, or a sulphonyloxy group, such as C_{1-6} alkanesulphonyloxy for example methanesulphonyloxy, benzenesulphonyloxy or 4-methylbenzenesulphonyloxy.

25 The reaction between the compounds of the formulae (III) and (IV) is conveniently performed at a non-extreme temperature for example -25°C to $+50^\circ\text{C}$ and more conveniently 0°C to $+30^\circ\text{C}$ and most conveniently at ambient temperature.

The reaction is typically performed in a substantially inert organic solvent for example an aprotic solvent such as acetonitrile or diethyl ether.

30 The reaction of the compounds of the formulae (III) and (IV) is believed to proceed via the formation of the lactone of the formula (V).

- 4 -



wherein P¹ and R¹ are as hereinbefore defined.

5 The compound of the formula (IV) acts as a base which is believed to convert the carboxylic acid function of the compound of the formula (III) to a carboxylate anion and which then displaces the leaving group L to form the lactone. The lactone is believed to be ring-opened by nucleophilic attack of the compound of the formula (IV) to form the compound of the formula (I).

10 Therefore another aspect of the present invention provides a process for preparing a compound of the formula (I) or salt thereof as hereinbefore defined which comprises reacting a lactone of the formula (V) with a compound of the formula (IV) and thereafter, if necessary, removing any protecting groups and/or forming a salt.

 The reaction between the compounds of the formulae (IV) and (V) takes place under
15 conditions analogous to those for the reaction of compounds of the formulae (III) and (IV).

 In another aspect the present invention provides a process for preparing a compound of the formula (V) as hereinbefore defined which comprises reacting a compound of the formula (III) with a non-nucleophilic base. In this way the base converts the carboxylic acid function of the compound of the formula (III) to a carboxylate anion which displaces L to
20 form the lactone. However the non-nucleophilic base does not substantially react further with the lactone which may be isolated.

Suitable non-nucleophilic bases include both organic and inorganic bases.

 Preferably the base is an inorganic base such as an alkali metal or alkaline earth metal carbonate or bicarbonate for example sodium bicarbonate, potassium carbonate, sodium
25 carbonate or potassium bicarbonate. Suitably the reaction is performed under biphasic conditions with the compound of the formula (III) dissolved in an aprotic organic solvent such as acetonitrile, diethyl ether or dichloromethane which is stirred, typically vigorously, with an aqueous solution of the base at a non-extreme temperature for example at ambient

- 5 -


temperature. The reaction may be monitored by thin layer chromatography or any other convenient methodology and, after a suitable period of time, the organic phase may be separated and worked-up to provide the compound of the formula (V). In an alternative the reaction is performed in the presence of a phase transfer catalyst for example benzyl
 5 trimethylammonium chloride, again with stirring at a non-extreme temperature.

In an alternative the non-nucleophilic base, for reacting with a compound of the formula (III), may be an organic base for example a tertiary amine such as di-isopropylethylamine. The reaction of a non-nucleophilic organic base with a compound of the formula (III) is typically performed under conditions analogous to those for the reaction of
 10 compound of the formulae (III) and (IV).

The present invention provides flexibility. In an advantageous aspect, it provides a "one-pot" reaction for preparing a compound of the formula (I) from the compounds of the formulae (III) and (IV). In another aspect, it can provide the compound of the formula (V) as a useful intermediate which can be reacted with a variety of compounds of the formula (IV).

15 The compounds of the formula (V) form another aspect of this invention.

Certain compounds of the formula (V) have been disclosed in the literature, in particular in the literature relating to polymers. Accordingly, the present invention provides a compound of the formula (VI):



(VI)

20 wherein P¹ is hydrogen or a protecting group and R^{1a} is a group R¹ as defined herein except that when P¹ is hydrogen, n-butyl, isopropyl, ethyl or allyl (-CH₂CH=CH₂), R^{1a} is not hydrogen and when P¹ is benzyl, R^{1a} is not hydrogen, methyl or isopropyl. In a particular
 25 aspect R^{1a} is not hydrogen.


Preferably, in the compounds of the formula (VI), P¹ is benzyl or C₁₋₆alkyl, for example methyl, ethyl, n-propyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl.

- 6 -


Preferred values of R^{1a} in the compounds of the formula (VI) are as described herein in relation to R^1 in the compounds of the formula (I).

Particular compounds of this invention include 3R-isobutyl-4-oxo-2S-oxetane carboxylic acid tert butyl ester and 3R-(4-benzyloxybutyl)-4-oxo-2S-oxetane carboxylic acid
5 tert butyl ester.

In a preferred aspect, the process of the present invention provides compounds of the formula (Ia):



10 wherein P^1 , R^1 and Z are as hereinbefore defined, from compounds of the formulae (III) and (IV). The reaction is believed to proceed via the formation of the lactone of the formula (Va):



15 wherein P^1 and R^1 are as hereinbefore defined. Preferred and particular values for P^1 , R^1 and Z in the compounds of the formulae (Ia) and (Va) are as described for the compounds of the formulae (I) and (V) respectively. Thus in a further aspect the present invention provides the compounds of the formula (Va) wherein R^1 is R^{1a} and P^1 and R^{1a} are as defined as in relation to formula (VI) hereinabove.

20 The compounds of the formula (III) form another aspect of this invention. Certain compounds of the formula (III) have been disclosed in the literature.

Accordingly the present invention provides a compound of the formula (VII):



- 7 -

wherein P¹ is hydrogen or a protecting group, R¹ is as herein defined and L¹ is a sulphonyloxy group or halo except that:

- i) when P¹ is hydrogen and R¹ is methyl or ethyl, L¹ is not bromo;
- ii) when P¹ is hydrogen and R¹ is methyl, L¹ is not chloro;
- 5 iii) when P¹ is isopropyl and R¹ is methyl, L¹ is not chloro or iodo.


Preferably in the compounds of the formula (VII), P¹ is benzyl or C₁₋₆alkyl for example methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl.

Preferably L¹ is bromo, chloro or iodo.

Preferred values of R¹ in the compounds of the formula (VII) are as described herein
10 in relation to R¹ in the compounds of the formula (I).

Particular compounds of this invention include 3R-chloro-2S-isobutylbutan-1,4-dioic acid 4-tert-butyl ester and 3R-chloro-2S-(4-benzyloxybutyl)butan-1,4-dioic acid 4-tert-butyl ester.

The compounds of the formula (III) may be prepared by reacting a dianion of the
15 formula (VIII):



wherein P¹ and R¹ are as hereinbefore defined, with a source of the group L.

Suitable sources of halo include carbon tetrachloride and carbon tetrabromide.

- 20 Typically the dianion of the formula (VIII) is formed by reacting the corresponding neutral compound with a non-nucleophilic base, for example lithium di-isopropylamide at low temperatures (-78°C) to form the dianion which is then reacted with the source of the group L.

The neutral compounds corresponding to the formula (VIII) are known in, or may be made by, the methods of the literature.

- 25 As stated hereinbefore the reaction of the compounds of the formulae (III) and (IV), or the reaction of the compounds of the formulae (IV) and (V), provides the compounds of the formula (I) or a salt thereof. The compounds of the formula (I) are optionally protected on the carboxylic acid function with a protecting group P¹.

- 8 -

The protecting group P¹ may in general be chosen from any of the groups described in the literature or known to the skilled chemist as appropriate for the protection of the carboxyl group, and may be introduced by conventional methods.

Protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.

Specific examples of protecting groups are given below for the sake of convenience, in which "lower" signifies that the group to which it is applied preferably has 1-4 carbon atoms. It will be understood that these examples are not exhaustive. Where specific examples of methods for the removal of protecting groups are given below these are similarly not exhaustive. The use of protecting groups and methods of deprotection not specifically mentioned is of course within the scope of the invention.

A carboxyl protecting group may be the residue of an ester-forming aliphatic or araliphatic alcohol or of an ester-forming silanol (the said alcohol or silanol preferably containing 1-20 carbon atoms).

Examples of carboxy protecting groups include straight or branched chain (1-12C)alkyl groups (eg isopropyl, *t*-butyl); lower alkoxy lower alkyl groups (eg methoxymethyl, ethoxymethyl, isobutoxymethyl); lower aliphatic acyloxy lower alkyl groups, (eg acetoxymethyl, propionyloxymethyl, butyryloxymethyl, pivaloyloxymethyl); lower alkoxycarbonyloxy lower alkyl groups (eg 1-methoxycarbonyloxyethyl, 1-ethoxycarbonyloxyethyl); aryl lower alkyl groups (eg benzyl, *p*-methoxybenzyl, *o*-nitrobenzyl, *p*-nitrobenzyl, benzhydryl and phthalidyl); tri(lower alkyl)silyl groups (eg trimethylsilyl and *t*-butyldimethylsilyl); tri(lower alkyl)silyl lower alkyl groups (eg trimethylsilylethyl); and (2-6C)alkenyl groups (eg allyl and vinylethyl).

Methods particularly appropriate for the removal of carboxyl protecting groups include for example acid-, base-, metal- or enzymically-catalysed hydrolysis.

Any other functional group in the compounds of the formulae (III)-(V) may be protected as necessary. Such protecting groups may in general be chosen from any of the groups described in the literature or known to the skilled chemist as appropriate for the protection of the group in question, and may be introduced by conventional methods. Such

- 9 -

protecting groups may be removed by any convenient method as described in the literature or known to the skilled chemist as appropriate for the removal of the protecting group in question, such methods being chosen so as to effect removal of the protecting group with minimum disturbance of groups elsewhere in the molecule.

- 5 Examples of hydroxyl protecting groups include lower alkyl groups (eg t-butyl), lower alkenyl groups (eg allyl); lower alkanoyl groups (eg acetyl); lower alkoxycarbonyl groups (eg t-butoxycarbonyl); lower alkenyloxycarbonyl groups (eg allyloxycarbonyl); aryl lower alkoxycarbonyl groups (eg benzoyloxycarbonyl, p-methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl);
- 10 tri lower alkylsilyl (eg trimethylsilyl, t-butyldimethylsilyl) and aryl lower alkyl (eg benzyl) groups.

- Examples of amino protecting groups include formyl, aralkyl groups (eg benzyl and substituted benzyl, p-methoxybenzyl, nitrobenzyl and 2,4-dimethoxybenzyl, and triphenylmethyl); di-p-anisylmethyl and furylmethyl groups; lower alkoxycarbonyl (eg
- 15 t-butoxycarbonyl); lower alkenyloxycarbonyl (eg allyloxycarbonyl); aryl lower alkoxycarbonyl groups (eg benzyloxycarbonyl, p-methoxybenzyloxycarbonyl, o-nitrobenzyloxycarbonyl, p-nitrobenzyloxycarbonyl); trialkylsilyl (eg trimethylsilyl and t-butyldimethylsilyl); alkylidene (eg methylidene); benzylidene and substituted benzylidene groups.

- 20 Methods appropriate for removal of hydroxy and amino protecting groups include, for example, acid-, base-, metal- or enzymically-catalysed hydrolysis, for groups such as p-nitrobenzyloxycarbonyl, hydrogenation and for groups such as o-nitrobenzyloxycarbonyl, photolytically.

- The compounds of the formula (I) wherein P¹ is hydrogen or an activated derivative
- 25 thereof, optionally wherein the hydroxy group in -CH(OH)- is protected, may be reacted with hydroxylamine, O-protected hydroxylamine or a salt thereof (followed by deprotection as necessary) to provide the hydroxamic acid compounds of the formula (II) as hereinbefore described.

- The compound of the formula (I) may be reacted in the form of the acid or an
- 30 activated derivative thereof such as an acid halide, acid anhydride or an 'activated' ester such as 1H-benzo[1,2,3]triazol-1-yl, 1-hydroxy-benzo[1,2,3]triazole, pentafluorophenyl or 2,4,5-

- 10 -

trichlorophenyl. The reaction of the compound of the formula (I) and hydroxylamine is performed under standard conditions. Typically the reaction of an activated ester of a compound of the formula (I) and hydroxylamine or O-protected hydroxylamine (for example protected with benzyl, *t*-butyl or silyl) is performed in the presence of a base, for example 2,6-lutidine in an anhydrous aprotic solvent, for example dimethylformamide, at a non-extreme temperature, for example in the region -30° to +25°, preferably about 0°C.

The processes of this invention may provide the compounds of the formula (I) in the form of a salt. In one aspect the compound is in the form of a pharmaceutically acceptable salt. Suitable pharmaceutically acceptable salts include acid addition salts such as hydrochloride, hydrobromide, citrate and maleate salts and salts formed with phosphoric and sulphuric acid. In another aspect suitable salts are base salts such as an alkali metal salt for example sodium or potassium, an alkaline earth metal salt for example calcium or magnesium, or organic amine salt for example triethylamine. In another aspect the compound is in the form of a non-pharmaceutically acceptable salt which may be a useful intermediate in preparing pharmaceutically acceptable salts of either of the compounds of the formula (I) or (II).

In the compounds of the formula (I), Z may be -CHR²COOP² wherein P² is hydrogen or a protecting group. Such compounds may be deprotected (P² is hydrogen) and reacted with a compound of the formula (IX):



wherein R³ and R⁴ are as herein defined under standard peptide coupling conditions. Alternatively a corresponding compound of the formula (II) may be deprotected (P² is hydrogen) and reacted with a compound of the formula (IX) under standard peptide coupling conditions.

Thus in another aspect the present invention provides a process for preparing compounds of the formula (II) which comprises reacting compounds of the formulae (III) and (IV) (or compounds of the formulae (IV) and (V)) and, subsequently reacting the product with hydroxylamine, O-protected hydroxylamine or a salt thereof.

- 11 -

The compounds of the formulae (I) and (II) may be formulated and tested according to the methods of the literature.

In the compounds of the formulae (I) and (II), R¹-R⁴ may have any value known for this structure in the TNF-inhibition literature and, in particular, known in the list of 5 disclosures provided hereinbefore.

More particularly:

R¹ is alkyl; alkenyl; alkynyl; phenylalkyl; heteroarylalkyl; cycloalkylalkyl;
cycloalkenylalkyl; phenylalkoxyalkyl; heteroarylalkoxyalkyl;

10 C₁₃₋₂₄ hydrocarbon chain optionally interrupted by one or more non-adjacent nitrogen, oxygen, sulphur, CO, SO, SO₂ groups;

R² is the characterising group of a non-natural α -amino acid in which any functional groups may be protected;

15 the side chain of a naturally occurring amino acid in which any functional groups may be protected;

20 CR^xR^yR^z wherein each of R^x, R^y, R^z is independently hydrogen, alkyl, alkenyl, alkynyl, phenylalkyl, halo, cyano, carboxy, alkoxycarbonyl, phenyl, heteroaryl, or R^x and R^y together with the carbon atom to which they are linked form a cycloalkyl or heterocyclic ring, or R^x, R^y and R^z together with the carbon atom to which they are linked form a bicyclic ring for example adamantyl;

25 phenyl, pyridyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, pyrazolyl, thiopyrazolyl, isoxazoliny, benzimidazolyl, benzoxazolyl or benzthiazolyl, any of which is optionally substituted;

30 R³ is CHR^aR^b wherein R^a and R^b independently represent phenyl or heteroaryl, which rings may be optionally linked by a bond or a C₁₋₄ alkylene or C₂₋₄alkenylene bridge, either of which may be interrupted by oxygen or sulphur;

- 12 -

-(Z-O)_n-Z wherein Z is C₁₋₆alkyl optionally interrupted by one or more non-adjacent sulphur or nitrogen atoms, n is >1;

- 5 C₃₋₈cycloalkyl or C₄₋₈cycloalkenyl; perfluoro C₁₋₄alkyl; alkyl; hydrogen; phenylalkyl; phenyl; heteroaryl; naphthyl;

R⁴ is hydrogen or alkyl.

- 10 Suitably alkyl (in "alkyl" and in any term containing "alkyl") is C₁₋₁₂alkyl, preferably C₁₋₆alkyl. Suitably alkenyl is C₂₋₁₂alkenyl, preferably C₂₋₆alkenyl. Suitably alkynyl is C₂₋₆alkynyl. Suitably cycloalkyl is C₃₋₈cycloalkyl.

- Any alkyl, cycloalkyl, cycloalkoxy, naphthyl, phenyl or heteroaryl ring is optionally substituted by one, two or three substituents selected from alkyl, alkoxy, alkylthio, phenoxy, 15 phenylalkoxy, halo, cyano, carboxy, hydroxy, amino, alkylamino, dialkylamino, mercapto, alkylaminosulphonyl, dialkylaminosulphonyl, cyanoalkyl, aminoalkyl, alkanoylamino, alkoxycarbonylamino, alkanoyl, trifluoromethyl, alkanoylamino, aryl, phenyl, arylalkyl, aryloxy, arylalkoxy, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, alkoxycarbonyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, hydroxyethyl, perfluoroC₁₋ 20 4alkyl, alkylsulphiny, alkylsulphonyl, nitro, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, benzyl, guanidine, pyrrolidino, morpholino or piperidino.

Favourably:

- R¹ is hydrogen, C₁₋₈alkyl, C₂₋₆alkenyl, C₂₋₆alkynyl, C₃₋₈cycloalkyl, aryl, heteroaryl, heterocyclyl, arylC₁₋₆alkyl, heteroarylC₁₋₆alkyl, heterocyclylC₁₋₆alkyl or 25 C₃₋₈cycloalkylC₁₋₆alkyl;
- R² is C₁₋₆alkyl, C₂₋₆alkenyl, arylC₁₋₆alkyl, heteroarylC₁₋₆alkyl or the side-chain of a naturally occurring amino acid;
- R³ is hydrogen, C₁₋₆alkyl, C₃₋₈cycloalkyl, C₄₋₈cycloalkenyl, arylC₁₋₆alkyl, heteroarylC₁₋₆alkyl or heterocyclylC₁₋₆alkyl;
- 30 R⁴ is hydrogen or C₁₋₆alkyl; or R³ or R⁴ together with the nitrogen atom to which they are joined form a heterocyclic ring;

- 13 -

wherein any group or ring, in R^1 - R^4 , is optionally substituted, and wherein "aryl in the terms
 "aryl" and "aryl C_{1-6} alkyl" typically means phenyl or naphthyl, preferably phenyl, and
 "heteroaryl" in the terms "heteroaryl" and "heteroaryl C_{1-6} alkyl" means an aromatic mono- or
 bicyclic 5-10 membered ring with up to five ring heteroatoms selected from nitrogen, oxygen
 5 and sulphur. (Examples of 'heteroaryl' include thienyl, pyrrolyl, furanyl, imidazolyl,
 thiazolyl, pyrimidinyl, pyridinyl, indolyl, benzimidazolyl, benzthiazolyl, quinolinyl and
 isoquinolinyl). "Heterocyclyl" in the term "heterocyclyl C_{1-6} alkyl" means a non-aromatic
 mono- or bicyclic 5-10 membered ring with up to five ring hetero atoms selected from
 nitrogen, oxygen and sulphur. (Examples of "heterocyclyl" include pyrrolidinyl, morpholinyl,
 10 piperidinyl, dihydropyridinyl and dihydropyrimidinyl).

Any group or ring in R^1 - R^4 may be optionally substituted, for example by up to three
 substituents which may be the same or different. Typical substituents include: hydroxy,
 C_{1-6} alkoxy for example methoxy, mercapto, C_{1-6} alkylthio for example methylthio, amino,
 C_{1-6} alkylamino for example methylamino, di- $(C_{1-6}$ alkyl)amino for example dimethylamino,
 15 carboxy, carbamoyl, C_{1-6} alkylcarbamoyl for example methylcarbamoyl, di- C_{1-6} alkylcarbamoyl
 for example dimethylcarbamoyl, C_{1-6} alkylsulphonyl for example methylsulphonyl,
 arylsulphonyl for example phenylsulphonyl, C_{1-6} alkylaminosulphonyl for example
 methylaminosulphonyl, di- $(C_{1-6}$ alkyl)aminosulphonyl for example dimethylamino-sulphonyl,
 nitro, cyano, cyano C_{1-6} alkyl for example cyanomethyl, hydroxy C_{1-6} alkyl for example
 20 hydroxymethyl, amino C_{1-6} alkyl for example aminoethyl, C_{1-6} alkanoylamino for example
 acetamido, C_{1-6} alkoxycarbonylamino for example methoxycarbonylamino,
 C_{1-6} alkanoyl for example acetyl, C_{1-6} alkanoyloxy for example acetoxy, C_{1-6} alkyl for example
 methyl, ethyl, isopropyl or tert-butyl, halo for example fluoro, chloro or bromo,
 trifluoromethyl, aryl for example phenyl, aryl C_{1-6} alkyl for example benzyl, aryloxy for
 25 example phenoxy, aryl C_{1-6} alkoxy for example benzyloxy, heteroaryl, heteroaryl C_{1-6} alkyl,
 heterocyclyl and heterocyclyl C_{1-6} alkyl. The term "side chain of a naturally occurring amino
 acid" means the side chain X of an amino acid NH_2 -CHX-COOH. Suitable amino acids
 include alanine, arginine, aspartic acid, cysteine, asparagine, glutamine, histidine, homoserine,
 isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, serine, threonine,
 30 tryptophan, tyrosine and valine.

- 14 -

The compounds of the formulae (I) and (II) possess a number of chiral centres, at the carbon atom adjacent to the HONHOC- group, at $-\text{CHR}^2-$, at $-\text{CHR}^1-$ (when R^1 is not hydrogen) and possibly in the variables R^1-R^4 . The processes of the present invention may be used to prepare diastereoisomers and mixtures thereof that inhibit TNF Convertase and/or

5 inhibit matrix metalloproteinase enzymes.

Favoured groups for R^1 include C_{1-8} alkyl for example isopropyl, n-propyl, isobutyl, sec-butyl, n-butyl, tert-butyl, isopentyl, n-pentyl, hexyl, heptyl or octyl; C_{1-8} alkyl interrupted by an oxygen or sulphur atom for example methoxypropyl, ethoxyethyl, propoxymethyl, ethylthioethyl or methylthiopropyl; phenyl C_{1-6} alkyl for example benzyl, phenethyl, phenylpropyl or phenylbutyl; aryl C_{1-6} alkyl interrupted by oxygen or sulphur for example benzyloxybutyl or benzyloxypropyl; C_{3-8} cycloalkyl for example cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl; aryl C_{1-6} alkyl interrupted by oxygen or sulphur for example benzyloxybutyl or benzyloxypropyl; or C_{3-8} cycloalkyl C_{1-6} alkyl for example cyclopropylmethyl, cyclopropylethyl, cyclobutylmethyl, cyclopentylmethyl or

15 cyclohexylmethyl.

Preferably R^1 is isobutyl.

There is a chiral centre at $-\text{CHR}^1-$ (when R^1 is not hydrogen); it is preferred that this centre has the configuration indicated in formula (X) hereinafter. For most values of R^1 this centre will have the R-stereochemistry under the Cahn-Prelog-Ingold sequence rules.

20 Favoured groups for R^2 include C_{1-6} alkyl for example methyl, ethyl, isopropyl, n-propyl, n-butyl, isobutyl, sec-butyl, tert-butyl, isopentyl, n-pentyl or hexyl; C_{1-6} alkyl interrupted by an oxygen or sulphur atom for example methoxyethyl, methoxypropyl, methylthioethyl or 1,1-dimethylmethylthiomethyl (MeSCMe_2-); or phenyl C_{1-6} alkyl for example benzyl or phenethyl.

25 Preferably R^2 is isobutyl, tert-butyl, 1,1-dimethylmethylthiomethyl or benzyl with tert-butyl being most preferred.

The chiral centre at $-\text{CHR}^2-$ preferably has the configuration indicated in formula (X) hereinafter. For most of R^2 this centre will have the S-stereochemistry.

Favoured groups for R^3 include C_{1-6} alkyl for example methyl, ethyl, n-propyl, isopropyl, tert-butyl or n-butyl; C_{1-6} alkyl interrupted by an oxygen or sulphur atom for

30

- 15 -


example hydroxyethyl, methoxyethyl, methylthioethyl or ethoxyethyl; C₂₋₆alkyl substituted by amino, C₁₋₆alkylamino or C₂₋₆dialkylamino; C₂₋₆alkyl substituted by either amino, C₁₋₆alkylamino or di-C₁₋₆alkylamino; phenylC₁₋₆alkyl for example benzyl, phenethyl or phenylpropyl; heterocyclicalkyl for example 2-morpholinoethyl, 2-piperazinoethyl, 2-(N-methylpiperazino)ethyl or 2-piperidinoethyl; or C₃₋₈cycloalkylC₁₋₆alkyl for example cyclopropylmethyl, cyclobutylmethyl or cyclopentylmethyl.

Preferably R³ is methyl, ethyl, n-propyl, isobutyl, tert-butyl or benzyl. Of these methyl is most preferred.

Favoured groups for R⁴ are hydrogen and C₁₋₆alkyl for example methyl or ethyl.

10 Preferably R⁴ is hydrogen.

A particularly suitable class of compounds prepared by the processes of the present invention is that of formula (X):



15 wherein R¹, R², R³ and R⁴ are as hereinbefore defined.

A preferred class of compound of the formula (X) is that wherein R¹ is isobutyl; R² is isobutyl, tert-butyl, 1,1-dimethylmethylthiomethyl or benzyl; R³ is methyl, ethyl, n-propyl, isobutyl, tert-butyl, 2-dimethylaminoethyl or benzyl; and R⁴ is hydrogen or methyl.

20 The following Examples illustrate the invention:

LDA means lithium di-isopropylamide

THF means tetrahydrofuran

25

Example 1**N²-[3S-Hydroxy-2R-isobutyl-4-*tert*-butyloxysuccinyl]-L-*tert*-leucine-N¹-methanamide**

5 a) To a stirred solution of LDA [45.5 mmol ; prepared by addition of 2.5 M *n*-butyl lithium (18.2 ml , 45.5 mmol) in hexane to a solution of diisopropylamine (6.3 ml , 48.3 mmol) in dry THF (20 ml) at -78°C] cooled to -78°C under argon was added dropwise a solution of 2R-isobutyl-butan-1,4-dioic acid-4-*tert*-butyl ester^{Ref 1} (5.0 g , 21.7 mmol) in dry THF (15 ml). The mixture was stirred for 45 minutes at -78°C and a solution of carbon
10 tetrachloride (2.3 ml , 23.9 mmol) in dry THF (3 ml) was added slowly, dropwise over ca. 8 minutes avoiding that the internal temperature rise above -65°C. The mixture was allowed to stir at -78°C for 30 minutes, warmed to room temperature and stirred for one hour at room temperature. The solution was cooled to -78°C and quenched by addition of HCl (2N, 3.3 ml). The solution was warmed to room temperature and extracted with diethyl ether. The
15 combined organic extracts were dried over MgSO₄, filtered and the solvents were removed to give directly one crude single isomer. The residue was purified by flash chromatography on silica using acetonitrile as eluant to give 3R-chloro-2S-isobutylbutan-1,4-dioic acid-4-*tert*-butyl ester (5.6 g , 98 %) as a pale brown oil :

¹H-NMR (CDCl₃) : 0.94 (d, 3H, J = 4.8 Hz) , 0.95 (d, 3H, J = 4.8 Hz) , 1.48 (s, 9H) , 1.55 (m,
20 1H) , 1.65-1.8 (m, 2H) , 3.05-3.1 (m, 1H) , 4.41 (d, 1H, J = 8.1 Hz) ;
MS (EI) : 264 (M{³⁵Cl} + H⁺) and 266 (M{³⁷Cl} + H⁺).

b) To a stirred solution of 3R-chloro-2S-isobutylbutan-1,4-dioic acid-4-*tert*-butyl ester (4.0 g , 15 mmol) in acetonitrile (100 ml) was added L-*tert*-leucine N-methanamide
25 (2.8 g , 19.4 mmol). The mixture was stirred at room temperature for 24 hours. A further quantity of acetonitrile (25 ml) was added and the mixture stirred for 12 hours. The solvents were evaporated in vacuo and the residue partitioned between water and ethyl acetate. The combined organic extracts were dried over MgSO₄, filtered and the solvents were removed. The residue was purified by flash chromatography on silica using acetonitrile-dichloromethane
30 (gradient from 1/4 to 1/3) as eluant to give N²-[3S-hydroxy-2R-isobutyl-4-*tert*-butyloxysuccinyl]-L-*tert*-leucine-N¹-methanamide (2.48 g , 45 %) as a white solid :

- 17 -

¹H-NMR (CDCl₃) : 0.92 (d, 3H, J = 6.2 Hz) , 0.96 (d, 3H, J = 6.2 Hz) , 0.99 (s, 9H) , 1.47 (s, 9H) , 1.55-1.75 (m, 3H) , 2.75 (m, 1H) , 2.79 (d, 3H, J = 5.1 Hz) , 3.73 (d, 1H, J = 5.9 Hz) , 4.1 (m, 1H) , 4.13 (d, 1H, J = 8.8 Hz) , 5.88 (m, 1H) , 6.68 (d, 1H, J = 9.1 Hz) ;

MS (EI) : 373 (M + H⁺).


5

A small quantity of unreacted 3R-chloro-2S-isobutylbutan-1,4-dioic acid-4-*tert*-butyl ester (336 mg) was recovered from the chromatography.

Example 2

10

3R-Isobutyl-4-oxo-2S-oxetane carboxylic acid *tert*-butyl ester



15 To a stirred solution of 3R-chloro-2S-isobutylbutan-1,4-dioic acid-4-*tert*-butyl ester (2.3 g , 8.7 mmol) in diethyl ether (50 ml) was added an aqueous solution (5%) of NaHCO₃ (45 ml) and the biphasic mixture was vigorously stirred at room temperature for 48 hours. The layers were separated and the organic phase was washed with water, dried over MgSO₄, filtered and the solvents were removed to give directly 3R-isobutyl-4-oxo-2S-oxetane

20 carboxylic acid *tert*-butyl ester (1.3 g , 68 %) as a brown oil :

¹H-NMR (CDCl₃) : 0.94 (d, 3H, J = 6.2 Hz) , 0.98 (d, 3H, J = 6.2 Hz) , 1.52 (s, 9H) , 1.7-1.85 (m, 3H) , 3.7 (m, 1H) , 4.47 (d, 1H, J = 4.03 Hz) ;

MS (EI) : 229 (M + H⁺).

25

Example 3**N²-[3S-Hydroxy-2R-isobutyl-4-*tert*-butyloxysuccinyl]-L-*tert*-leucine-N¹-methanamide**

- 5 To a stirred solution of 3R-isobutyl-4-oxo-2S-oxetane carboxylic acid *tert*-butyl ester (1.2 g, 5.3 mmol) in acetonitrile (15 ml) was added L-*tert*-leucine N-methanamide (0.98 g, 6.8 mmol). The mixture was stirred at room temperature for 36 hours. The solvents were evaporated in vacuo and the residue partitioned between water and diethyl ether. The combined organic extracts were dried over MgSO₄, filtered and the solvents were removed.
- 10 The residue was purified by flash chromatography on silica using acetonitrile-dichloromethane (gradient from 1/9 to 3/7) as eluant to give N²-[3S-hydroxy-2R-isobutyl-4-*tert*-butyloxysuccinyl]-L-*tert*-leucine-N¹-methanamide (1.27 g, 66 %) as a white solid :
- ¹H-NMR (CDCl₃) : 0.92 (d, 3H, J = 6.2 Hz) , 0.96 (d, 3H, J = 6.2 Hz) , 0.99 (s, 9H) , 1.47 (s, 9H) , 1.55-1.75 (m, 3H) , 2.75 (m, 1H) , 2.79 (d, 3H, J = 5.1 Hz) , 3.73 (d, 1H, J = 5.9 Hz) , 4.15 (m, 1H) , 4.13 (d, 1H, J = 8.8 Hz) , 5.88 (m, 1H) , 6.68 (d, 1H, J = 9.1 Hz) ;
- MS (EI) : 373 (M + H⁺).

Example 4**20 3R-Isobutyl-4-oxo-2S-oxetane carboxylic acid *tert*-butyl ester**

- To a stirred solution of 3R-chloro-2S-isobutyl-butan-1,4-dioic acid-4-*tert*-butyl ester (103 mg, 0.4 mmol) in dichloromethane (10 ml) was added an aqueous solution (10%) of NaHCO₃ (5 ml) followed by benzyl trimethylammonium chloride (7 mg, 0.04 mmol) and the
- 25 biphasic mixture was vigorously stirred at room temperature for 9 hours. The layers were separated and the organic phase was washed with water, dried over MgSO₄, filtered and the solvents were removed to give directly 3R-isobutyl-4-oxo-2S-oxetane carboxylic acid *tert*-butyl ester (50 mg, 57 %) as a pale brown oil :
- ¹H-NMR (CDCl₃) : 0.94 (d, 3H, J = 6.2 Hz) , 0.98 (d, 3H, J = 6.2 Hz) , 1.52 (s, 9H) , 1.7-1.85
- 30 (m, 3H) , 3.7 (m, 1H) , 4.47 (d, 1H, J = 4.03 Hz) .

Example 5**N²-[3S-Hydroxy-2R-isobutyl-4-*tert*-butyloxysuccinyl]-L-*tert*-leucine-N¹-dimethylamide**

5 In a manner analogous to that described in Example 1 (b), to a solution of 3R-chloro-2S-isobutylbutan-1,4-dioic acid-4-*tert*-butyl ester (500 mg, 1.89 mmol) in acetonitrile (7 ml) was added L-*tert*-leucine-N-dimethylamide^{NOTE} (448 mg, 2.83 mmol). The mixture was stirred at room temperature for 24 hours. The mixture was poured into aqueous NH₄Cl (10%) and extracted with ethyl acetate. The combined organic extracts were washed with water, dried
10 over MgSO₄, filtered and the solvents were removed. The residue was purified by flash chromatography on silica using acetonitrile-dichloromethane (1/4) as eluant to give N²-[3S-hydroxy-2R-isobutyl-4-*tert*-butyloxysuccinyl]-L-*tert*-leucine-N¹-dimethylamide (395 mg, 54 %) as a gum which solidified :

¹H-NMR (CDCl₃) : 0.92 (d, 3H, J = 5.5 Hz) , 0.95 (d, 3H, J = 5.8 Hz) , 0.98 (s, 9H) , 1.47
15 (s, 9H) , 1.55-1.7 (m, 3H) , 2.72 (m, 1H) , 2.95 (s, 3H) , 3.1 (s, 3H) , 3.86 (s br, 1H) , 4.07 (m, 1H) , 4.86 (d, 1H, J = 9.5 Hz) , 6.61 (d, 1H, J = 9.2 Hz) ;
MS (EI) : 409 (M + Na⁺).

^{NOTE} L-*tert*-leucine-N-dimethylamide was prepared by the reaction of L-*tert*-leucine with
20 triphosgene to give 3-(S)-*tert*-butyl oxazolidine-1,4-dione which was then treated with a saturated ethereal solution of dimethylamine.

Example 6**N²-[3S-Hydroxy-2R-isobutyl-4-*tert*-butyloxysuccinyl]-L-*tert*-leucine-N¹-(2-dimethylaminoethyl)amide**

In a manner analogous to that described in Example 1 (b), to a solution of 3R-chloro-2S-isobutylbutan-1,4-dioic acid-4-*tert*-butyl ester (500 mg, 1.89 mmol) in acetonitrile (7 ml)
30 was added L-*tert*-leucine-N-(2-dimethylaminoethyl)amide^{NOTE} (455 mg, 2.2 mmol). The mixture was stirred at room temperature for 48 hours. The mixture was poured into aqueous

- 20 -

NH₄Cl (10%) and extracted with ethyl acetate. The combined organic extracts were washed with water, dried over MgSO₄, filtered and the solvents were removed. The residue was purified by flash chromatography on silica using methanol-dichloromethane (1/9) as eluant to give N²-[3S-hydroxy-2R-isobutyl-4-*tert*-butoxysuccinyl]-L-*tert*-leucine-N¹-(2-

5 dimethylaminoethyl)amide(437 mg , 54 %) as a gum:

¹H-NMR (CDCl₃) : 0.93 (d, 3H, J = 5.8 Hz) , 0.96 (d, 3H, J = 6.2 Hz) , 1.0 (s, 9H) , 1.48 (s, 9H) , 1.55-1.71 (m, 3H) , 2.23 (s, 6H) , 2.46 (m, 2H) , 2.76 (m, 1H) , 3.34 (m, 2H) , 4.11 (d, 1H, J = 3.3 Hz) , 4.19 (d, 1H, J = 9.2 Hz) , 6.6 (m, 2H) ;

MS (EI) : 430 (M + H⁺) and 452 (M + Na⁺).

10

^{NOTE} L-*tert*-leucine-2-dimethylaminoethylamide was prepared by the reaction of L-*tert*-leucine with triphosgene to give 3-(S)-*tert*-butyl oxazolidine-1,4-dione which was then treated with N,N-dimethyl ethylenediamine.

15 Example 7

N²-[3S-Hydroxy-2R-(4'-benzyloxy)butyl-4-*tert*-butoxysuccinyl]-L-*tert*-leucine-N¹-methylamide

20 In a manner analogous to that described in Example 1 (a), to a stirred solution of LDA [11.24 mmol ; prepared by addition of 2.5 M n-butyl lithium (4.5 ml , 11.24 mmol) in hexane to a solution of diisopropylamine (1.57 ml , 11.24 mmol) in dry THF (4 ml) at -78°C] cooled to -78°C under argon was added dropwise a solution of 2R-(4'-benzyloxy)butyl-butan-1,4-dioic acid-4-*tert*-butyl ester ^{Ref 2} (1.8 g , 5.35 mmol) in dry THF (2 ml). The mixture was

25 stirred for 70 minutes at -78°C and a solution of carbon tetrachloride (0.566 ml , 5.89 mmol) in dry THF (1 ml) was added slowly, dropwise over ca. 8 minutes avoiding that the internal temperature rise above -65°C. The mixture was allowed to stir at -78°C for 60 minutes and quenched by addition of HCl (2N). The solution was warmed to room temperature and extracted with diethyl ether. The combined organic extracts were dried over MgSO₄, filtered

30 and the solvents were removed to give directly crude 3R-chloro-2S-(4'-benzyloxy)butyl-

- 21 -

butan-1,4-dioic acid-4-*tert*-butyl ester (2.13 g , 100 %) as a brown oil used as such in the following step:

¹H-NMR (CDCl₃) : 1.3-1.75 (m, 6H) , 1.47 (s, 9H) , 3.04 (m, 1H) , 3.47 (t, 2H, J = 6.3 Hz) , 4.37 (d, 1H, J = 9.1 Hz) , 4.49 (s, 2H) , 7.29-7.34 (m, 5H);

5 MS (EI) : 371 (M{³⁵Cl} + H⁺) and 373 (M{³⁷Cl} + H⁺).

In a manner analogous to that described in Example 1 (b), to a solution of 3R-chloro-2S-(4'-benzyloxy)butyl-butan-1,4-dioic acid-4-*tert*-butyl ester (1.9 g , 5.12 mmol) in acetonitrile (40 ml) was added L-*tert*-leucine-N-methylamide (738 mg , 6.15 mmol). The mixture was stirred at room temperature for 16 hours. The mixture was poured into aqueous NH₄Cl (10%) and extracted with ethyl acetate. The combined organic extracts were washed with water, dried over MgSO₄, filtered and the solvents were removed. The residue was purified by flash chromatography on silica using acetonitrile-dichloromethane (gradient from 3/17 to 7/13) as eluant to give N²-[3S-hydroxy-2R-(4'-benzyloxy)butyl-4-*tert*-

15 butyloxysuccinyl]-L-*tert*-leucine-N¹-methylamide (520 mg , 27 %) as a pale yellow gum :

¹H-NMR (CDCl₃) : 0.98 (s, 9H) , 1.46 (s, 9H) , 1.6-1.9 (m, 6H) , 2.66 (m, 1H) , 2.77 (d, 3H, J = 4.8 Hz) , 3.46 (t, 2H, J = 6.3 Hz) , 3.74 (s br, 1H) , 4.12 (m, 2H) , 4.49 (m, 2H) , 5.79 (m, 1H) , 6.71 (d, 1H, J = 9.2 Hz) 7.33-7.36 (m, 5H);

MS (EI) : 479 (M + H⁺).

20

A quantity of unreacted 3R-chloro-2S-(4'-benzyloxy)butyl-butan-1,4-dioic acid-4-*tert*-butyl ester (412 mg) was recovered from the chromatography.

References


25

1. British Biotechnology Ltd (M. J. Crimmin, P. R. Beckett and M. H. Davis) PCT International Application WO 94/21625.
2. M. R. Gowravaram, J. S. Johnson, D. Delecki, E. R. Cook, B. E. Tomczuk, A. K. Ghose, A. M. Mathiowetz, J. C. Spurlino, B. Rubin et al., J. Med. Chem., 38(14), 2570-81, 1995.

30


CLAIMS

1. A process for preparing a compound of the formula (I) or a salt thereof:



wherein P^1 is hydrogen or a protecting group. Z is a group $-CHR^2COOP^2$ or $-CHR^2CONR^3R^4$ wherein P^2 is hydrogen or a protecting group and R^1 - R^4 are values known in the TNF-inhibitor art;

- 10 which process comprises reacting a compound of the formula (III):




wherein L is a leaving group, with a compound of the formula (IV).



and thereafter if necessary:


- i) removing any protecting groups,
20 ii) forming a salt

2. A process for preparing a compound of the formula (I) or a salt thereof.



wherein P^1 , R^1 and Z are as defined in claim 1, which comprises reacting a compound of the formula (V)

- 23 -



(V)

wherein P¹ and R¹ are as defined in claim 1 with a compound of the formula (IV):

5




(IV)

wherein Z is as defined in claim 1 and thereafter if necessary.

- i) removing any protecting groups,
- ii) forming a salt.

10

3. A process for preparing a compound of the formula (V) as defined in claim 2 which comprises reacting a compound of the formula (VII):




(VII)

15

wherein P¹ and R¹ are as defined in claim 1 and L¹ is a leaving group with a non-nucleophilic base.

4. A compound of the formula (VI):

20




(VI)

wherein P¹ is as defined in claim 1 and R^{1a} is a group R¹ as defined herein except that when P¹ is n-butyl, isopropyl, ethyl or allyl (-CH₂CH=CH₂), R^{1a} is not hydrogen and when P¹ is
25 benzyl, R^{1a} is not hydrogen, methyl or isopropyl.

- 24 -

5. A compound according to claim 4 which is of the formula (VIa):



5 wherein P¹ and R¹ᵃ are as defined in claim 4.


6. A compound according to either claim 4 or 5 wherein R¹ᵃ is C₁-₈alkyl, C₁-₈alkyl interrupted by an oxygen or sulphur atom, phenylC₁-₆alkyl, arylC₁-₆alkyl interrupted by oxygen or sulphur, C₃-₈cycloalkyl, arylC₁-₆alkyl interrupted by oxygen or sulphur or C₃-
 10 g cycloalkyl-
 C₁-₆alkyl.

7. A compound according to any one of claims 4 to 6 wherein R¹ᵃ is isobutyl.

- 15 8. A compound according to claim 5 selected from a C₁-₆alkyl ester of 3R-isobutyl-4-oxo-2S-oxetane carboxylic acid and a C₁-₆alkyl ester of 3R-(4-benzyloxybutyl)-4-oxo-2S-oxetane carboxylic acid.

9. A compound of the formula:

20




wherein P¹ is hydrogen or a protecting group, R¹ is as defined in claim 1 and L¹ is a halo or sulphonyloxy group except that:

- 20 i) when P¹ is hydrogen and R¹ is methyl or ethyl, L¹ is not bromo;
 ii) when P¹ is hydrogen and R¹ is methyl, L¹ is not chloro;
 iii) when P¹ is isopropyl and R¹ is methyl, L¹ is not chloro or iodo.

- 25 -

10. A process for preparing a compound of the formula (II):



5

wherein R¹ and Z are as defined in claim 1 which comprises:

- i) reacting a compound of the formula (III) with a compound of the formula (IV) to form a compound of the formula (V):
- 10 ii) reacting the compound of the formula (V) wherein P¹OOC- is HOOC- or an activated derivative thereof with hydroxylamine, O-protected hydroxylamine or a salt thereof; and thereafter as necessary:
 - a) removing any protecting group;
 - b) forming a salt.

15

20

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/00913

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07C231/14 C07D305/12 C07C55/32 C07C309/63 C07C259/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 02446 A (BRITISH BIO TECHNOLOGY ;DICKENS JONATHON PHILIP (GB); CRIMMIN MICH) 3 February 1994 cited in the application see claims 15-17 ---	1, 10
X	BAJWA J S ET AL: "PREPARATION OF CHIRAL SUBSTITUTED SUCCINIC ACIDS" JOURNAL OF ORGANIC CHEMISTRY, vol. 48, no. 7, April 1983, pages 1114-1116, XP000615419 see page 1114; figure 8 --- -/--	4

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

22 July 1998

Date of mailing of the international search report

04/08/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Pauwels, G

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 98/00913

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No. ...
X	MILLER M J ET AL: "ENANTIOSELECTIVE SYNTHESES OF 3-SUBSTITUTED 4-(ALKOXYCARBONYL)-2-AZETIDINONES FROM MALIC ACID" JOURNAL OF ORGANIC CHEMISTRY, vol. 47, no. 25, December 1982, pages 4928-4933, XP000615420 see page 4930; figures 20SS, 20RR ---	4
X	CHEMICAL ABSTRACTS, vol. 12, no. 8, 20 April 1918 Columbus, Ohio, US; "IV. Experiments with iodosuccinic acid" page 808; XP002069979 see abstract & B. HOLMBERG: ARKIV KEMI MIN. GEOL., vol. 6, no. 23, 1917, ---	3,4,9
X	"Biochemicalien organische verbindingen en diagnostica (Sigma Catalogue)" 1996, SIGMA CHEMIE XP002069977 Compounds C 5019, C 5144 see page 254 ---	9
X	"Biochemicalien organische verbindingen en diagnostica (Sigma Catalogue)" 1996, SIGMA CHEMIE XP002069978 Compound B 4033 see page 198 ---	9
X	M. ARTICO ET AL.: "Sintesi di beta-carbossi-beta-arilalanine" IL FARMACO, EDIZIONE SCIENTIFICA, vol. XX, no. 7, 1965, PAVIA IT, pages 523-531, XP002069975 see page 530; table IV ---	9
X	M. ARTICO: "Sintesi dell betacarbossitirosina" IL FARMACO, EDIZIONE SCIENTIFICA, vol. XVII, no. 12, 1963, PAVIA IT, pages 981-989, XP002069976 see page 986, last paragraph - page 987, paragraph 1 -----	9

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 98/ 00913

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 1-10
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
The expressions: "protecting group", "values known in the TNF-inhibitor art", "leaving group" are vague and cannot be used as a basis for a prior art search. For the purposes of the search, the values given in the description for the affected substituents have been used.

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/GB 98/00913

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9402446 A	03-02-1994	AT 162183 T	15-01-1998
		AT 151414 T	15-04-1997
		AU 4715293 A	14-02-1994
		AU 661410 B	20-07-1995
		AU 4715393 A	14-02-1994
		CA 2140626 A	03-02-1994
		CY 1944 A	16-05-1997
		CZ 9500157 A	18-10-1995
		DE 4393452 T	01-06-1995
		DE 69309686 D	15-05-1997
		DE 69309686 T	24-07-1997
		DE 69316367 D	19-02-1998
		DE 69316367 T	10-06-1998
		DK 651739 T	18-08-1997
		EP 0651738 A	10-05-1995
		EP 0651739 A	10-05-1995
		EP 0754688 A	22-01-1997
		FI 950262 A	20-01-1995
		WO 9402447 A	03-02-1994
		GB 2268933 A,B	26-01-1994
		GB 2268934 A,B	26-01-1994
		GB 2287023 A,B	06-09-1995
		HK 149396 A	16-08-1996
		HU 9500187 A	28-11-1995
		HU 70552 A	30-10-1995
		JP 7509459 T	19-10-1995
		JP 7509460 T	19-10-1995
		NO 950226 A	20-01-1995
		NZ 254862 A	27-02-1996
		PL 307171 A	15-05-1995
		SK 7895 A	11-07-1995
		US 5643964 A	01-07-1997
		US 5700838 A	23-12-1997
		ZA 9305351 A	14-02-1994
		ZA 9305352 A	16-05-1994

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.